TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $40.67.

A number of analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.50% of the company’s stock.

Institutional Trading of TG Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after acquiring an additional 209,190 shares during the last quarter. State Street Corp lifted its position in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after purchasing an additional 2,398,015 shares in the last quarter. Soleus Capital Management L.P. grew its holdings in TG Therapeutics by 5.8% during the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock valued at $80,705,000 after purchasing an additional 146,702 shares during the period. Clearbridge Investments LLC bought a new stake in TG Therapeutics during the fourth quarter valued at about $55,237,000. Finally, Northern Trust Corp raised its stake in shares of TG Therapeutics by 8.6% in the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after buying an additional 120,785 shares during the period. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Down 0.8 %

TGTX stock opened at $39.86 on Friday. TG Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $43.32. The company has a market capitalization of $6.26 billion, a price-to-earnings ratio of -398.56 and a beta of 2.30. The business’s 50 day moving average price is $34.37 and its two-hundred day moving average price is $30.34. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. As a group, analysts forecast that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.